In this study, we demonstrated that KCTD10 suppresses lung cancer proliferation and metastasis by promoting β-catenin degradation, leading to decreasing PD-L1 expression and enhanced efficacy of anti-PD-1 immunotherapy in lung cancer and lung cancer brain metastases. Here, PDCD1 is linked to lung carcinoma.